Brokerages predict that Medidata Solutions Inc (NASDAQ:MDSO) will report earnings per share (EPS) of $0.47 for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Medidata Solutions’ earnings, with estimates ranging from $0.44 to $0.52. Medidata Solutions reported earnings of $0.42 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 11.9%. The business is scheduled to issue its next quarterly earnings report on Thursday, October 17th.
On average, analysts expect that Medidata Solutions will report full year earnings of $1.84 per share for the current year, with EPS estimates ranging from $1.77 to $1.93. For the next year, analysts forecast that the firm will report earnings of $2.14 per share, with EPS estimates ranging from $2.00 to $2.27. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Medidata Solutions.
Medidata Solutions (NASDAQ:MDSO) last posted its quarterly earnings data on Monday, July 22nd. The company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.31. Medidata Solutions had a net margin of 6.43% and a return on equity of 8.64%. The firm had revenue of $180.50 million for the quarter, compared to analysts’ expectations of $179.95 million. During the same period in the previous year, the company posted $0.43 EPS. The company’s quarterly revenue was up 15.8% compared to the same quarter last year.
NASDAQ MDSO traded up $0.02 on Friday, hitting $91.41. 214,955 shares of the stock were exchanged, compared to its average volume of 1,031,504. Medidata Solutions has a 52-week low of $60.10 and a 52-week high of $98.60. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.56 and a quick ratio of 2.57. The company has a market cap of $5.70 billion, a P/E ratio of 95.22, a price-to-earnings-growth ratio of 6.03 and a beta of 1.21. The business’s 50-day moving average price is $90.91.
In other news, Director Robert Taylor sold 3,294 shares of the business’s stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $90.88, for a total transaction of $299,358.72. Following the transaction, the director now directly owns 41,757 shares in the company, valued at approximately $3,794,876.16. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 4.70% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. BlackRock Inc. boosted its holdings in Medidata Solutions by 4.3% in the first quarter. BlackRock Inc. now owns 7,293,413 shares of the company’s stock worth $534,167,000 after purchasing an additional 297,812 shares in the last quarter. Clearbridge Investments LLC boosted its holdings in Medidata Solutions by 2.0% in the first quarter. Clearbridge Investments LLC now owns 2,545,149 shares of the company’s stock worth $186,407,000 after purchasing an additional 48,943 shares in the last quarter. Champlain Investment Partners LLC boosted its holdings in Medidata Solutions by 1.5% in the first quarter. Champlain Investment Partners LLC now owns 2,390,155 shares of the company’s stock worth $175,055,000 after purchasing an additional 35,405 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in Medidata Solutions by 6.0% in the first quarter. Janus Henderson Group PLC now owns 1,837,555 shares of the company’s stock worth $134,583,000 after purchasing an additional 103,716 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. boosted its holdings in Medidata Solutions by 16.8% in the first quarter. Nikko Asset Management Americas Inc. now owns 1,259,943 shares of the company’s stock worth $92,278,000 after purchasing an additional 181,553 shares in the last quarter.
Medidata Solutions Company Profile
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development and commercialization of new therapies. The company's platform solutions include data capture and management, and trial planning and management.
Read More: The Structure of a Futures Contract
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.